CoChat

Destruction of tumor vasculature and abated tumor growth upon VEGF blockade is driven by proapoptotic protein Bim in endothelial cells

Open access
Naik, Edwina, O'Reilly, Lorraine A., Asselin-Labat, Marie-Liesse, Merino, Delphine, Lin, Ann, Cook, Michele, Coultas, Leigh, Bouillet, Philippe, Adams, Jerry M., Strasser, Andreas · 2011 · Journal of Experimental Medicine

The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.

Abstract

For malignant growth, solid cancers must stimulate the formation of new blood vessels by producing vascular endothelial growth factor (VEGF-A), which is required for the survival of tumor-associated vessels. Novel anticancer agents that block VEGF-A signaling trigger endothelial cell (EC) apoptosis and vascular regression preferentially within tumors, but how the ECs die is not understood. In this study, we demonstrate that VEGF-A deprivation, provoked either by drug-induced tumor shrinkage or direct VEGF-A blockade, up-regulates the proapoptotic BH3 (Bcl-2 homology 3)-only Bcl-2 family member Bim in ECs. Importantly, the tumor growth inhibitory activity of a VEGF-A antagonist required Bim-induced apoptosis of ECs. These findings thus reveal the mechanism by which VEGF-A blockade induces EC apoptosis and impairs tumor growth. They also indicate that drugs mimicking BH3-only proteins may be exploited to kill tumor cells not only directly but also indirectly by ablating the tumor vasculature.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20100951

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. GCV treatment reduces VEGF expression in B16.F1 tumors. (A) Western blot analysis of the expression of the two predominant isoforms of tumor-associated VEGF in homogenates of TK-expressing B16.F1 melanomas generated from tumors grown in WT mice treated with three daily injections of GCV and harvested on day 4. (B) VEGF ELISA performed on lysates from B16.F1 tumors treated as in A. Data represent mean ± SEM of five independent mice per genotype and treatment condition. (C) Representative photomicrographs of B16.F1 tumors treated as in A. Inset shows magnification of the boundary of VEGF-expressing and non-expressing tumor cells. Bar, 200 µm.
Figure 1. GCV treatment reduces VEGF expression in B16.F1 tumors. (A) Western blot analysis of the expression of the two predominant isoforms of tumor-associated VEGF in homogenates of TK-expressing B16.F1 melanomas generated from tumors grown in WT mice treated with three daily injections of GCV and harvested on day 4. (B) VEGF ELISA performed on lysates from B16.F1 tumors treated as in A. Data represent mean ± SEM of five independent mice per genotype and treatment condition. (C) Representative photomicrographs of B16.F1 tumors treated as in A. Inset shows magnification of the boundary of VEGF-expressing and non-expressing tumor cells. Bar, 200 µm.CC BY-NC-SA · PubMed Central
Figure 2. Bim is required for the tumor shrinkage–induced apoptosis of tumor-associated ECs. (A) TK-expressing B16.F1 melanomas were grown subcutaneously in WT or Bim−/− mice until they reached a volume of ∼50 mm3, whereupon the animals were treated with three daily injections of GCV or saline. On day 4, sections of tumors were stained for CD31 (brown). N, necrosis. (B) Quantification of microvessel density in tumor tissue sections described in A. Data represent the mean ± SEM (n = 4 per genotype and treatment condition). (C) FACS analysis of single-cell suspensions of tumors from saline- or GCV-treated WT or Bim−/− mice. Data represent the mean ± SEM (n = 5 per genotype and treatment condition). (D) Tumors were subjected to TUNEL and CD31 staining to identify apoptotic ECs (yellow). Bars: (A) 100 µm; (D) 40 µm.
Figure 2. Bim is required for the tumor shrinkage–induced apoptosis of tumor-associated ECs. (A) TK-expressing B16.F1 melanomas were grown subcutaneously in WT or Bim−/− mice until they reached a volume of ∼50 mm3, whereupon the animals were treated with three daily injections of GCV or saline. On day 4, sections of tumors were stained for CD31 (brown). N, necrosis. (B) Quantification of microvessel density in tumor tissue sections described in A. Data represent the mean ± SEM (n = 4 per genotype and treatment condition). (C) FACS analysis of single-cell suspensions of tumors from saline- or GCV-treated WT or Bim−/− mice. Data represent the mean ± SEM (n = 5 per genotype and treatment condition). (D) Tumors were subjected to TUNEL and CD31 staining to identify apoptotic ECs (yellow). Bars: (A) 100 µm; (D) 40 µm.CC BY-NC-SA · PubMed Central
Figure 3. Drug-induced tumor shrinkage causes up-regulation of a Bim transcriptional reporter and elevated Bim protein in tumor-associated ECs. TK-expressing B16.F1 melanomas were grown and treated as described in Generation of B16.F1 and 3LL-LLC cell lines stably expressing TK-SR39 TK. (A) Representative histograms depict EC populations with high β-galactosidase (β-gal) activity. Solid lines depict β-galactosidase activity in ECs from saline-treated tumors, dashed lines depict β-galactosidase activity in ECs from GCV-treated tumors, and closed regions represent a no-FDG negative control. (B) Bar graph depicting the percentages of tumor-associated ECs with high levels of β-galactosidase activity. Data represent the mean ± SEM (n = 3–5 for both saline and GCV treatments). (C) Tumor-associated ECs were purified from >10 WT mice treated twice with saline or GCV and assessed for Bim expression. HSP70 served as a loading control, and the lysate from an Eµ-myc lymphoma served as a positive (+) control. Black lines indicate that intervening lanes have been spliced out.
Figure 3. Drug-induced tumor shrinkage causes up-regulation of a Bim transcriptional reporter and elevated Bim protein in tumor-associated ECs. TK-expressing B16.F1 melanomas were grown and treated as described in Generation of B16.F1 and 3LL-LLC cell lines stably expressing TK-SR39 TK. (A) Representative histograms depict EC populations with high β-galactosidase (β-gal) activity. Solid lines depict β-galactosidase activity in ECs from saline-treated tumors, dashed lines depict β-galactosidase activity in ECs from GCV-treated tumors, and closed regions represent a no-FDG negative control. (B) Bar graph depicting the percentages of tumor-associated ECs with high levels of β-galactosidase activity. Data represent the mean ± SEM (n = 3–5 for both saline and GCV treatments). (C) Tumor-associated ECs were purified from >10 WT mice treated twice with saline or GCV and assessed for Bim expression. HSP70 served as a loading control, and the lysate from an Eµ-myc lymphoma served as a positive (+) control. Black lines indicate that intervening lanes have been spliced out.CC BY-NC-SA · PubMed Central
Figure 4. Bim is required for the death of tumor-associated ECs and inhibition of tumor growth on VEGF neutralization. (A) WT or Bim−/− mice bearing subcutaneous 3LL-LLCs were treated with anti-VEGF antibody or a control Ig isotype–matched antibody when the tumors reached a volume of ∼50 mm3. CD31 immunohistochemistry revealed tumor vascularization at day 6 of treatment. (B) FACS analysis was used to enumerate viable tumor-associated ECs. Data represent mean ± SEM (n = 5–7 for each treatment and genotype). (C) Bar graph depicts the percentages of tumor-associated ECs with high levels of β-galactosidase (β-gal) activity. Mice were treated with two daily injections of control IgG or anti-VEGF antibody and analyzed 1 d after cessation of treatment. Data represent the mean ± SEM (n = 3–5 for both control Ig and anti-VEGF treatments). (D) Day 6 tumors from saline- or anti-VEGF antibody–treated WT or Bim−/− mice were subjected to TUNEL and CD31 staining. Inset shows magnification of a boxed region showing an apoptotic EC (yellow). Boxes highlight regions containing apoptotic ECs. Bars: (A) 200 µm; (D) 40 µm. (E) WT, Bim−/−, Bid−/−, and Puma−/− mice bearing 3LL-LLC were treated with anti-VEGF neutralizing antibody as described in Mice, expression constructs, and tumor models. FACS analysis was used to enumerate viable tumor-associated ECs. Data represent mean ± SEM (n = 3–5 for each treatment and genotype of mice). The data for WT and Bim−/− mice are the same as those shown in B and are reproduced in this panel to facilitate comparison. n.s., not significant. (F) The growth of 3LL-LLC in WT or Bim−/− mice treated with VEGF neutralizing antibody or a control Ig antibody. Mice were sacrificed when tumors exceeded a diameter of 1 cm on any orthogonal parameter. Data represent mean tumor volume and SEs (n = 5–17 per time point and genotype of mice; *, P = 0.047 control Ig–treated Bim−/− mice vs. control Ig–treated WT mice; **, P = 0.0002 anti-VEGF antibody–treated WT mice vs. control Ig–treated WT mice; ***, P = 0.0001 anti-VEGF–treated Bim−/− mice vs. anti-VEGF antibody–treated WT mice). All statistical comparisons were made at day 8 of treatment. Arrows designate the days of treatment. (G) WT CD45.1+ (closed bars) or Bim−/− CD45.2+ (open bars) recipient mice were reconstituted with unfractionated bone marrow from Bim−/− CD45.2+ or WT CD45.1+ donors, respectively. The hematopoietic compartment was reconstituted for 8 wk before inoculation of 3LL-LLC cells, and mice were subjected to treatment as described in Mice, expression constructs, and tumor models. FACS analysis was used to enumerate viable tumor-associated ECs. Data represent mean ± SEM (n = 4–13 for each treatment and genotype of mice).
Figure 4. Bim is required for the death of tumor-associated ECs and inhibition of tumor growth on VEGF neutralization. (A) WT or Bim−/− mice bearing subcutaneous 3LL-LLCs were treated with anti-VEGF antibody or a control Ig isotype–matched antibody when the tumors reached a volume of ∼50 mm3. CD31 immunohistochemistry revealed tumor vascularization at day 6 of treatment. (B) FACS analysis was used to enumerate viable tumor-associated ECs. Data represent mean ± SEM (n = 5–7 for each treatment and genotype). (C) Bar graph depicts the percentages of tumor-associated ECs with high levels of β-galactosidase (β-gal) activity. Mice were treated with two daily injections of control IgG or anti-VEGF antibody and analyzed 1 d after cessation of treatment. Data represent the mean ± SEM (n = 3–5 for both control Ig and anti-VEGF treatments). (D) Day 6 tumors from saline- or anti-VEGF antibody–treated WT or Bim−/− mice were subjected to TUNEL and CD31 staining. Inset shows magnification of a boxed region showing an apoptotic EC (yellow). Boxes highlight regions containing apoptotic ECs. Bars: (A) 200 µm; (D) 40 µm. (E) WT, Bim−/−, Bid−/−, and Puma−/− mice bearing 3LL-LLC were treated with anti-VEGF neutralizing antibody as described in Mice, expression constructs, and tumor models. FACS analysis was used to enumerate viable tumor-associated ECs. Data represent mean ± SEM (n = 3–5 for each treatment and genotype of mice). The data for WT and Bim−/− mice are the same as those shown in B and are reproduced in this panel to facilitate comparison. n.s., not significant. (F) The growth of 3LL-LLC in WT or Bim−/− mice treated with VEGF neutralizing antibody or a control Ig antibody. Mice were sacrificed when tumors exceeded a diameter of 1 cm on any orthogonal parameter. Data represent mean tumor volume and SEs (n = 5–17 per time point and genotype of mice; *, P = 0.047 control Ig–treated Bim−/− mice vs. control Ig–treated WT mice; **, P = 0.0002 anti-VEGF antibody–treated WT mice vs. control Ig–treated WT mice; ***, P = 0.0001 anti-VEGF–treated Bim−/− mice vs. anti-VEGF antibody–treated WT mice). All statistical comparisons were made at day 8 of treatment. Arrows designate the days of treatment. (G) WT CD45.1+ (closed bars) or Bim−/− CD45.2+ (open bars) recipient mice were reconstituted with unfractionated bone marrow from Bim−/− CD45.2+ or WT CD45.1+ donors, respectively. The hematopoietic compartment was reconstituted for 8 wk before inoculation of 3LL-LLC cells, and mice were subjected to treatment as described in Mice, expression constructs, and tumor models. FACS analysis was used to enumerate viable tumor-associated ECs. Data represent mean ± SEM (n = 4–13 for each treatment and genotype of mice).CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 31

Metadata

Authors
Naik, E., O'Reilly, L. A., Asselin-Labat, M.-L., Merino, D., Lin, A., Cook, M., Coultas, L., Bouillet, P., Adams, J. M., & Strasser, A.
Affiliations
  • The University of Melbourne (AU)
  • The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, Victoria 3052, Australia 1
  • Walter and Eliza Hall Institute of Medical Research (AU)
Corresponding author
Strasser, Andreas
Venue
Journal of Experimental Medicine
Published
2011-06-06
Volume
208
Issue
7
Pages
1351-1358
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2163882639
Cited by
31
References
29
Citations by year
2025: 1 · 2024: 2 · 2021: 2 · 2020: 2 · 2017: 4 · 2016: 2 · 2015: 2 · 2014: 5 · 2013: 3 · 2012: 6
FWCI
2.08
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
Funders
  • Leukemia and Lymphoma Society
  • National Institutes of Health
  • Genentech
  • Medical Research Council (461221)
  • National Health and Medical Research Council (461221, 516703, 461299)
  • National Cancer Institute (R01CA043540, CA 43540)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
Keywords
building information modeling, endothelial cell apoptosis, tumor vasculature, tumor growth inhibition, BH3-only proteins, Bcl-2 family proteins, tumor angiogenesis, vascular regression, anticancer agents
MeSH terms
Bcl-2-Like Protein 11, Animals, Antineoplastic Agents, Melanoma, Experimental, Membrane Proteins, Mice, Inbred C57BL, Mice, Transgenic, Proto-Oncogene Proteins, Recombinant Proteins, Thymidine Kinase, Ganciclovir, Gene Expression, Apoptosis, Mice, Knockout, Carcinoma, Lewis Lung, Vascular Endothelial Growth Factor A, Endothelial Cells, Cell Line, Tumor, Apoptosis Regulatory Proteins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Destruction of tumor vasculature and abated tumor growth upon VEGF blockade is driven by proapoptotic protein Bim in endothelial cells. https://app.cochat.ai/papers/10.1084/jem.20100951
The paper
Naik, E., O'Reilly, L. A., Asselin-Labat, M.-L., Merino, D., Lin, A., Cook, M., Coultas, L., Bouillet, P., Adams, J. M., & Strasser, A. (2011). Destruction of tumor vasculature and abated tumor growth upon VEGF blockade is driven by proapoptotic protein Bim in endothelial cells. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20100951

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.